Skip to main content
TipRanks
Go Ultimate75% OFF

Moderna (0A45) Share Price & Analysis

12 Followers

0A45 Stock Chart & Stats

$224.43-$10.54(-4.49%)
At close: 4:30 PM GMT
$100$200Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$221.60 - $233.00
52-Week Range
$22.25 - $280.82
Previous Close
$234.97
Volume
N/A
Average Volume (3M)
98.56K
Market Cap
$90.38B
Enterprise Value
$81.86B
Total Cash (Recent Filing)
$5.17B
Total Debt (Recent Filing)
$4.18B
Price to Earnings (P/E)
―
Beta
0.95
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The higher revenue framework indicates improving commercial execution and demand across Moderna’s portfolio. If sustained, stronger growth can support operating leverage, fund pipeline investment, and reduce dependence on a single seasonal COVID product over the next several quarters.

Oncology Breakthrough

Positive Phase 3 melanoma data provide meaningful validation for Moderna’s individualized cancer-vaccine platform and create a potential commercial franchise beyond respiratory vaccines. The result also supports further oncology development and could broaden the company’s long-term revenue base if approved.

Platform Diversification

Expansion from a predominantly COVID-focused business into influenza and combination respiratory vaccines strengthens product breadth and commercial resilience. Multiple approved products can improve customer relevance, create cross-selling opportunities, and support recurring seasonal revenue across international markets.

Bears Say

Persistent Losses

Large ongoing net and operating losses show that the current revenue base does not yet support Moderna’s cost structure. Continued losses can consume capital, delay sustainable profitability, and limit strategic flexibility unless commercial growth and expense reductions produce durable operating leverage.

Cash Burn

Meaningfully negative operating and free cash flow indicate that Moderna is not currently self-funding its business and pipeline investments. Even with improvement from the prior year, continued burn increases reliance on liquidity and financing until products generate consistently positive cash earnings.

Cost Pressure

Rapidly rising cost of sales threatens margin durability and shows that higher product volume is not automatically translating into stronger economics. Manufacturing-related costs, together with the separate litigation charge, could keep profitability volatile while the portfolio scales and pricing remains competitive.

Moderna News

0A45 FAQ

What was Moderna’s price range in the past 12 months?
Moderna lowest share price was $22.25 and its highest was $280.82 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $90.38B.
When is Moderna’s upcoming earnings report date?
Moderna’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 101 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Nov 06, 2026. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of -$1.096 by $1.476.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.08.
How many shares outstanding does Moderna have?
Moderna has 404,620,970 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of $0.38 in its last earnings report, beating expectations of -$1.096. Following the earnings report the stock price went up 7.392%.
Which hedge fund is a major shareholder of Moderna?
Hedge funds hold Moderna shares: the largest hedge-fund position in Moderna is 1,053,529,884 shares, and hedge funds decreased their holdings by 50.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology